

Clinical and immunologic features in severe and moderate forms of Coronavirus Disease

2019

Guang Chen^{1*}, Di Wu^{1*}, Wei Guo^{1*}, Yong Cao^{2*}, Da Huang^{1†}, Hongwu Wang^{1†}, Tao Wang^{2†},
Xiaoyun Zhang^{1†}, Huilong Chen¹, Haijing Yu¹, Xiaoping Zhang¹, Minxia Zhang³, Shiji Wu³,
Jianxin Song¹, Tao Chen¹, Meifang Han¹, Shusheng Li⁴, Xiaoping Luo⁵, Jianping Zhao², Qin
Ning¹

¹Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China

²Department of Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China

³Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong
University of Science and Technology, Wuhan, China

⁴ Department of Emergency Medicine, Tongji Hospital, Huazhong University of Science and
Technology, Wuhan, China

⁵Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China

* [†]Contributed equally.

Corresponding author:

Qin Ning, MD, PhD

Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan, China

No. 1095, Jiefang Avenue, Wuhan, China. 430030

Email: qning@vip.sina.com

Phone: +86 27 8366 2391

Fax: +86 27 8366 2391

30 Email:

31 Guang Chen: widechain@163.com

32 Di Wu: woody_1984@163.com

33 Wei Guo: 294571240@qq.com

34 Yong Cao: 2677877@qq.com

35 Da Huang: 413706477@qq.com

36 Hongwu Wang: hongwuwang@126.com

37 Tao Wang: wt7636@126.com

38 Xiaoyun Zhang: 403065840@qq.com

39 Huilong Chen: huilong_chen@126.com

40 Haijing Yu: 463104640@qq.com

41 Xiaoping Zhang: 503125569@qq.com

42 Minxia Zhang: 764180047@qq.com

43 Shiji Wu: 7212460@qq.com

44 Jianxin Song: jxsong@tjh.tjmu.edu.cn

45 Tao Chen: chentao_tjh@vip.sina.com

46 Meifang Han: 156755182@qq.com

47 Shusheng Li: shushengli16@sina.com

48 Xiaoping Luo: xpluo888@sina.com

49 Jianping Zhao: Zhaojp88@126.com

50 Qin Ning: qning@vip.sina.com

51

52

53 Abstract

54 **Background** Since late December, 2019, an outbreak of pneumonia cases caused by the
55 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and
56 continued to spread throughout China and across the globe. To date, few data on immunologic
57 features of Coronavirus Disease 2019 (COVID-19) have been reported.

58 **Methods** In this single-centre retrospective study, a total of 21 patients with pneumonia who
59 were laboratory-confirmed to be infected with SARS-CoV-2 in Wuhan Tongji hospital were
60 included from Dec 19, 2019 to Jan 27, 2020. The immunologic characteristics as well as their
61 clinical, laboratory, radiological features were compared between 11 severe cases and 10
62 moderate cases.

63 **Results** Of the 21 patients with COVID-19, only 4 (19%) had a history of exposure to the
64 Huanan seafood market. 7 (33.3%) patients had underlying conditions. The average age of
65 severe and moderate cases was 63.9 and 51.4 years, 10 (90.9%) severe cases and 7 (70.0%)
66 moderate cases were male. Common clinical manifestations including fever (100%, 100%),
67 cough (70%, 90%), fatigue (100%, 70%) and myalgia (50%, 30%) in severe cases and
68 moderate cases. PaO₂/FiO₂ ratio was significantly lower in severe cases (122.9) than
69 moderate cases (366.2). Lymphocyte counts were significantly lower in severe cases ($0.7 \times$
70 $10^9/L$) than moderate cases ($1.1 \times 10^9/L$). Alanine aminotransferase, lactate dehydrogenase
71 levels, high-sensitivity C-reactive protein and ferritin were significantly higher in severe cases
72 (41.4 U/L, 567.2 U/L, 135.2 mg/L and 1734.4 ug/L) than moderate cases (17.6 U/L, 234.4
73 U/L, 51.4 mg/L and 880.2 ug/L). IL-2R, TNF- α and IL-10 concentrations on admission were
74 significantly higher in severe cases (1202.4 pg/mL, 10.9 pg/mL and 10.9 pg/mL) than
75 moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 pg/mL). Absolute number of total T
76 lymphocytes, CD4⁺T cells and CD8⁺T cells decreased in nearly all the patients, and were
77 significantly lower in severe cases (332.5 , 185.6 and $124.3 \times 10^6/L$) than moderate cases
78 (676.5 , 359.2 and $272.0 \times 10^6/L$). The expressions of IFN- γ by CD4⁺T cells tended to be
79 lower in severe cases (14.6%) than moderate cases (23.6%).

80 **Conclusion** The SARS-CoV-2 infection may affect primarily T lymphocytes, particularly
81 CD4⁺T cells, resulting in significant decrease in number as well as IFN- γ production, which

82 may be associated with disease severity. Together with clinical characteristics, early
83 immunologic indicators including diminished T lymphocytes and elevated cytokines may
84 serve as potential markers for prognosis in COVID-19.

85

86 Keywords: SARS-CoV-2; COVID-19; cytokines; lymphocytes; IFN- γ

87

88 **Introduction**

89 Coronaviruses (CoV) are a large family of respiratory viruses that can cause diseases ranging
 90 from the common cold to the Middle-East Respiratory Syndrome (MERS) and the Severe
 91 Acute Respiratory Syndrome (SARS)^{1,2}, both of which are zoonotic in origin and induce fatal
 92 lower respiratory tract infection as well as extrapulmonary manifestations. The new
 93 coronavirus, designated as the severe acute respiratory syndrome coronavirus 2
 94 (SARS-CoV-2), is a member of Beta-CoV lineage B, which was first identified in Wuhan,
 95 China by the Chinese Center for Disease Control and Prevention (CDC)^{3,4}. Recent reports
 96 have provided evidence for person to person transmission of the SARS-CoV-2 in family and
 97 hospital settings^{5,6}. As of Feb 1, 2020, the number of SARS-CoV-2 cases globally had
 98 eclipsed 14000, exceeding the total number of SARS cases during the 2003 epidemic, and
 99 more than 300 people had now died. The outbreak of SARS-CoV-2-induced Coronavirus
 100 Disease 2019 (COVID-19) has put health authorities on high alert in China and across the
 101 globe.

102 It has been revealed that SARS-CoV-2 has a genome sequence 75% to 80% identical to the
 103 SARS-CoV and has more similarities to several bat coronaviruses³. Both clinical and
 104 epidemiological features of patients with COVID-19 have recently been reported,
 105 demonstrating that the SARS-CoV-2 infection can cause clusters of severe respiratory illness
 106 with clinical presentations greatly resembling SARS-CoV, leading to ICU admission and high
 107 mortality⁷. Clinical manifestations have included fever, fatigue, dry cough, shortness of breath,
 108 and acute respiratory distress syndrome (ARDS). Additionally, a study of the first 41
 109 laboratory-confirmed cases with COVID-19 showed that 63% of patients had lymphopenia,
 110 and cytokine storm could be associated with disease severity. However, little is known about
 111 immunologic features between severe and moderate forms of COVID-19⁷.

112 In this study, we performed a comprehensive evaluation of characteristics of 21 patients with
 113 COVID-19 admitted to Tongji Hospital, Wuhan. We aimed to compare the clinical and
 114 immunologic features between severe cases and moderate cases. These findings will help us
 115 extend our understanding of the pathophysiological mechanism of the SARS-CoV-2 infection.

116 **Patients and methods**

117 **Study participants**

118 From late Dec 19, 2019 to Jan 27, 2020, a total of 21 cases who initially presented with fever
119 or respiratory symptoms, with pulmonary infiltrates on chest computed tomography (CT)
120 scans in isolation ward of Department of Infectious Disease, Tongji hospital were later
121 confirmed to be infected with the novel coronavirus by the local health authority. Four cases
122 had a history of exposure to the Huanan seafood market.

123 We retrospectively evaluated and analyzed the medical history, physical examination, and
124 hematological, biochemical, radiological, microbiological and immunological evaluation
125 results obtained from these 21 patients with COVID-19. Epidemiological, clinical, laboratory,
126 and radiological characteristics and treatment as well as outcomes data were obtained from
127 electronic medical records. The data collection forms were reviewed independently by two
128 researchers.

129 The patients with $SpO_2 \leq 93\%$ or respiratory rates ≥ 30 per min were classified as having
130 severe COVID-19, those without above-mentioned signs as moderate cases.

131 Considering the emergence of COVID-19 cases during the influenza season, oseltamivir
132 (orally 75 mg twice daily) and antibiotics (oral and intravenous) were empirically
133 administered. Corticosteroid therapy (methylprednisolone) was given concomitantly to some
134 patients with COVID-19 by physicians. Oxygen support including nasal cannula and
135 non-invasive mechanical ventilation was provided to the patients according to the severity of
136 hypoxemia. After being identified as having laboratory-confirmed SARS-CoV-2 infection,
137 these patients were transferred to the designated hospital.

138 The study was approved by the Institutional Review Board of Tongji Hospital, Tongji Medical
139 College, Huazhong University of Science and Technology.

140

141 **Complication definitions**

142 ARDS and shock were defined according to the interim guidance of WHO for novel
143 coronavirus⁸.

144 Hypoxemia was defined as arterial oxygen tension (PaO_2) over inspiratory oxygen fraction
145 (FIO_2) of less than 300 mm Hg.

146 Acute kidney injury was identified and classified on the basis of the highest serum creatinine
147 level or urine output criteria according to the kidney disease improving global outcomes
148 classification.

149 Acute liver injury was defined as jaundice with a total bilirubin level of ≥ 3 mg/dl and an
150 acute increase in alanine aminotransferase of at least five times the upper limit of the normal
151 range and/or an increase in alkaline phosphatase of at least twice the upper limit of the normal
152 range.

153 Cardiac injury was diagnosed if serum levels of cardiac biomarkers were $>$ the 99th percentile
154 upper reference limit, or new abnormalities were shown in electrocardiography and
155 echocardiography.

156 Secondary infection including bacteria and fungus was diagnosed if the patients had clinical
157 symptoms or signs of nosocomial pneumonia or bacteremia, and was combined with a
158 positive culture of a new pathogen from a respiratory tract specimen or from blood samples
159 taken ≥ 48 h after admission.

160

161 **Laboratory measurements**

162 **Respiratory pathogen detection**

163 Respiratory specimens were collected by local CDC and then shipped to designated
164 authoritative laboratories to detect the SARS-CoV-2. The presence of SARS-CoV-2 in
165 respiratory specimens was detected by next-generation sequencing or real-time RT-PCR
166 methods. The primers and probe target to envelope gene of CoV were used and the sequences
167 were as follows: forward primer 5'-TCAGAATGCCAATCTCCCAAC-3'; reverse primer
168 5'-AAAGGTCCACCCGATACATTGA-3'; and the probe
169 5'-CY5-CTAGTTACTAGCCATCCTTACTGC-3'-BHQ1. Conditions for the amplifications
170 were 50°C for 15 min, 95°C for 3 min, followed by 45 cycles of 95°C for 15 s and 60°C for
171 30 s.

172

173 **Clinical laboratory measurements**

174 Initial clinical laboratory investigation included a complete blood count, serum biochemical

test (including liver and renal function, creatine kinase, lactate dehydrogenase, and electrolytes), coagulation profile, as well as immunological test (including serum cytokines, peripheral immune cells subsets and the expression of IFN- γ by immune cells). Respiratory specimens, including nasal and pharyngeal swabs, or sputum were tested to exclude evidence of other virus infection, including influenza, respiratory syncytial virus, avian influenza, parainfluenza virus and adenovirus using real-time RT-PCR assays approved by the China Food and Drug Administration. Routine bacterial and fungal examinations were also performed.

183

184 **Cytokine measurement**

To explore the impact of SARS-CoV-2 on the secretion of cytokines in the early phase of the infection, plasma cytokines including IL-1 β , IL-2R, IL-6, IL-8 (also known as CXCL8), IL-10, and TNF- α were measured using the sandwich enzyme-linked immune-sorbent assay (ELISA) method by micro-ELISA autoanalyser (Diasorin Etimax 3000, Germany) for all patients according to the manufacturer's instructions. The first initial blood samples were drawn shortly after hospital admission.

191

192 **Proportions analysis of peripheral blood immunological indicators**

The proportions and numbers of NK, CD4⁺T, CD8⁺T, Treg and B cells, and the expression of cell surface markers as well as IFN- γ expression by CD4⁺T, CD8⁺T and NK cells were studied in these patients with laboratory-confirmed SARS-CoV-2 infection who were reported by the local health authority.

197 PE-CD28/PE•CY7-CD8/PerCP-CD45/APC-HLADR/APC•CY7-CD3/V450-CD4,

198 FITC-CD45RA/PE-CD45RO/PE•CY7-CD127/PerCP-CD45/APC-CD25/APC•CY7-CD3/V4

199 50-CD4,

200 FITC-CD3/PE-CD8/PE•CY7-CD56/PerCP-CD45/APC-IFN- γ /APC•CY7-CD3/V450-CD4

multiple-color anti-human monoclonal antibodies (mAbs) combination reagents and matched isotype controls were used to determine the peripheral immune cell subsets within 2 days after admission. Peripheral blood mononuclear cells (PBMCs) were isolated immediately

204 from fresh blood and subjected to antibody staining followed by flow cytometry. All reagents
205 were purchased from Becton, Dickinson, and Company (BD, Franklin Lakes, USA). Cell
206 surface antigen staining for flow cytometry was conducted according to the standard
207 procedure of the BD Pharmingen protocol. All samples were detected by BD FACS Canto II
208 Flow Cytometry System and analyzed with the BD FACS Diva Software.

209

210 **Statistical analysis**

211 Continuous variables were expressed as mean (S.D.) and compared with the Mann-Whitney
212 U test; categorical variables were expressed as number (%) and compared by χ^2 test or
213 Fisher's exact test between moderate and severe case groups. A two-sided α of less than 0.05
214 was considered statistically significant. Statistical analyses were done using the SAS software,
215 version 9.4.

216

217 Results

218 Patient demographics and baseline characteristics of severe and moderate forms of 219 COVID-19

220 By Jan 22, 2020, a total of 21 admitted hospital patients with pneumonia were identified as
221 laboratory-confirmed SARS-CoV-2 infection in Wuhan Tongji hospital. Of these patients,
222 only four patients including a familial cluster of three confirmed cases had direct exposure to
223 Huanan seafood market. 11 (52.4%) patients with $SpO_2 \leq 93\%$ or respiratory rates ≥ 30 per min
224 who required high-flow nasal cannula or non-invasive mechanical ventilation using the
225 Bilevel Positive Airway Pressure (BiPAP) mode to correct hypoxemia, were classified as
226 having severe COVID-19, whereas 10 (47.6%) patients without above-mentioned signs as
227 moderate cases. 10 (90.9%) of severe cases and 7 (70%) of moderate cases were male (table
228 1). The mean age of the severe cases (63.9 years) was significantly older than moderate cases
229 (51.4 years). 90.9% of severe cases were above 50 years old, which was more frequent than
230 that of moderate cases (50%). 5 (45.5%) of severe cases and 2 (20%) moderate cases had
231 underlying diseases. Of 7 patients with underlying diseases, four patients had hypertension,
232 two had diabetes, and one had both hypertension and diabetes. The mean time from onset of
233 symptoms to first hospital admission was 7.3 days in severe cases and 5.5 days in moderate
234 cases.

235 Four of eleven severe cases died at an average of 20 days after the onset of the illness. Of
236 these four fatal cases, all of them were male and had age over 50 years old, and two had
237 hypertension. Mean age of fatal cases were 67.5 years old. Three of the fatal cases had
238 PaO_2/FiO_2 ratio ≤ 100 on admission.

239 Excluding one comatose patient without a clear history (classified as severe case), the most
240 common clinical manifestations at onset of illness include fever (100% of total cases), cough
241 (70% of severe cases, 90% of moderate cases), fatigue (100% of severe cases, 70% of
242 moderate cases) and myalgia (50% of severe cases, 30% of moderate cases). Less common
243 symptoms include sputum production (20% of severe cases, 30% of moderate cases), diarrhea
244 (10% of severe cases, 30% of moderate cases), headache (10% of severe cases, 10% of
245 moderate cases) and hemoptysis (10% of severe cases). All the severe cases developed

dyspnea, and nine of them had SpO₂<93% even with high-flow nasal cannula, who were then ventilated using the BiPAP mode to treat hypoxemia. The mean duration from illness onset to dyspnea was 8.6 days. Arterial blood gas (ABG) test was performed in 10 patients on admission (six severe and four moderate cases). Of them, PaO₂/FiO₂ ratio was significantly lower in severe cases (122.9 mmHg) than moderate cases (366.2 mmHg). Three severe cases had PaO₂/FiO₂ ratio ≤ 100, indicating severe ARDS.

252

253 **Laboratory findings and CT scans of severe and moderate forms of COVID-19**

254 The routine blood tests on admission of three (30%) moderate cases showed mild leucopenia
255 (white blood cell count (WBC) < 4 × 10⁹/L). WBC counts were normal or slightly increased
256 in all the severe cases. Both WBC and neutrophil counts were significantly higher in severe
257 cases (9.2 × 10⁹/L and 8.0 × 10⁹/L) than moderate cases (4.7 × 10⁹/L and 3.1 × 10⁹/L).
258 Whereas lymphocyte counts were significantly lower in severe cases (0.7 × 10⁹/L) than
259 moderate cases (1.1 × 10⁹/L). Lymphopenia (lymphocyte count <0.8 × 10⁹/L) was found in
260 8 (72.7%) severe cases and only 1 (10.0%) moderate cases (table 2).

261 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were
262 significantly higher in severe cases (41.4 U/L and 51.0 U/L) than moderate cases (17.6 U/L
263 and 24.2 U/L). Albumin concentrations were significantly lower in severe cases (31.5g/L)
264 than moderate cases (37.6g/L). Levels of lactate dehydrogenase (LDH) were significantly
265 higher in severe cases (567.2 U/L) than moderate cases (234.4 U/L).

266 Concentrations of serum high-sensitivity C-reactive protein (hsCRP) and ferritin on
267 admission were significantly elevated in severe cases (135.2 mg/L and 1734.4 ug/L) than
268 moderate cases (51.4 mg/L and 880.2 ug /L). Serum levels of procalcitonin on admission
269 tended to be higher in severe cases (0.5 ng/mL) than moderate cases (0.1 ng/mL). Activated
270 partial thromboplastin time (APTT) on admission was significantly shorter in severe cases
271 (36.2s) than moderate cases (44.6s). D-dimer levels on admission were markedly greater in
272 severe cases (8.2 ug/mL) than moderate cases (0.4 ug/mL).

273 Interstitial lung abnormalities were observed in chest CT scans of all patients on admission.
274 Of the 21 patients, 10 (90.1%) severe cases and 7 (70%) moderate cases had bilateral

involvement on admission (table 2). Later on, only one patient with moderate COVID-19 remained unilateral involvement. The typical findings of chest CT images of severe COVID-19 on admission showed bilateral ground glass opacity and subsegmental areas of consolidation (figure 1A), then progressed rapidly with mass shadows of high density in both lungs (figure 1B). Whereas the representative chest CT findings of moderate COVID-19 showed bilateral ground glass opacity (figure 1C). Later chest CT images revealed bilateral ground-glass opacity had been resolved (figure 1D).

Immunologic features of severe and moderate forms of COVID-19

Evaluation of plasma cytokines revealed that IL-2R, IL-6, IL-10, and TNF- α concentrations on admission were moderately elevated in the majority of severe cases (88.9%, 88.9%, 77.8%, and 88.9%), but only mildly increased (14.3%, 71.4%, 28.6%, and 42.9%) or remained within the normal range in moderate cases (table 3). IL-8 concentrations were elevated in few patients (22.2% severe cases, 14.3% moderate cases). IL-1 β concentrations were undetectable (<5pg/mL) in nearly all the patients with either severe or moderate COVID-19. IL-2R, TNF- α and IL-10 concentrations on admission were significantly higher in severe cases (1202.4 pg/mL, 10.9 pg/mL and 10.9 pg/mL) than moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 pg/mL).

Preliminary analysis of circulating immune cells subsets showed that absolute number of total T lymphocytes, CD4⁺T cells and CD8⁺T cells decreased in the majority of patients with either severe (100%, 100% and 87.5%) or moderate COVID-19 (83.3%, 100% and 83.3%), and total T lymphocytes, CD4⁺T cells and CD8⁺T cells counts were reduced more profoundly in severe cases (332.5, 185.6 and 124.3 $\times 10^6/L$) than moderate cases (676.5, 359.2 and 272.0 $\times 10^6/L$) (figure 2A, 2B). More severe cases (100%) had the proportion of HLA-DR⁺ expression on CD8⁺T cells (of > 35%) than moderate cases (25%). Reduction of B cells and NK cells counts tended to be more frequent in severe cases (37.5% and 75%) than moderate cases (16.7% and 33.3%), whereas the proportion of B cells was significantly higher in severe cases (26.5%) than moderate cases (12.0%). This could be partly due to the more significant decrease of T lymphocytes in severe cases. In addition, six (75.0%) of eight severe cases showed a broad,

304 significant decrease in all the lymphocytes subsets excluding B cells, with total T
 305 lymphocytes counts below $400 \times 10^6/L$, CD8⁺T cells counts below $150 \times 10^6/L$, and NK cells
 306 counts below $77 \times 10^6/L$. Of these six patients, three (50%) eventually died.
 307 Moreover, the frequencies of Treg (CD4⁺CD25⁺CD127^{low}+) and CD45RA⁺Treg decreased in
 308 nearly all the severe (60% and 100%) and moderate cases (100% and 100%), with
 309 CD45RA⁺Treg decreased more profoundly in severe cases (0.5%) than moderate cases (1.1%).
 310 The expressions of IFN- γ by CD4⁺T, CD8⁺T and NK cells were decreased in some patients
 311 with severe (50%, 16.7% and 16.7%) or moderate COVID-19 (14.3%, 0% and 14.3%). The
 312 expressions of IFN- γ by CD4⁺T cells tended to be lower in severe cases (14.6%) than
 313 moderate cases (23.6%) (figure 2C).

314

315 **Complications and clinical outcomes of COVID-19**

316 As for complications, nine (81.8%) severe cases and one (10%) moderate case developed
 317 ARDS, among them, three (27.3%) severe cases had confirmed severe ARDS by ABG test
 318 with $PaO_2/FiO_2 \leq 100$. One case developed multiple organ dysfunction syndrome (MODS),
 319 including acute kidney injury, cardiac injury and heart failure as well as pulmonary
 320 encephalopathy prior to admission. Another patient developed acute liver injury and
 321 disseminated intravascular coagulation in a short time. These two patients died soon
 322 afterwards. One patient with severe COVID-19 developed acute liver injury and was in
 323 recovery and discharged after a three-week hospitalization, with extracorporeal membrane
 324 oxygenation (ECMO) support. The chest CT scan afterwards showed improvement of
 325 bilateral ground-glass opacity and subsegmental areas of consolidation.

326 Of 21 patients, nine (42.9%) required non-invasive ventilation. 19 (90.5%) patients received
 327 antiviral therapy (oseltamivir and ganciclovir). All patients were given empirical
 328 antimicrobial treatment (moxifloxacin or cefoperazone-sulbactam). In Addition, most patients
 329 (85.7%) were administered corticosteroids (methylprednisolone). As of Feb 2, 2020, 4
 330 (36.4 %) of 11 severe cases and none (0.0 %) of the moderate cases have died, the average
 331 days from illness onset to death was 20 days. One severe and one moderate case have
 332 recovered. Patients were transferred to the designated hospital after being identified as having

333 laboratory-confirmed SARS-CoV-2 infection.

334

335 Discussion

336 This is the first preliminary study evaluating descriptively the immunologic characteristics of
 337 patients with laboratory-confirmed SARS-CoV-2 infection. Both clinical and epidemiological
 338 features of patients with COVID-19 have recently been reported^{5-7,9}. However, there is
 339 insufficient knowledge of pathophysiological parameters as well as immunologic indicators to
 340 understand the mechanism involved in COVID-19. Consistent with previous reports⁷, in this
 341 present study, a male predominance in the incidence of COVID-19 has been noted similar to
 342 that of SARS-CoV, indicating males are more susceptible to SARS-CoV-2 infection than
 343 females. Older males (>50 years old), in particular those with chronic comorbidities may be
 344 more likely to develop severe COVID-19, and associated with a high mortality (28.6% of
 345 males aged >50 years old with comorbidities). The most common clinical manifestations at
 346 onset of illness included fever, cough, fatigue and myalgia. Severe cases were more likely to
 347 have dyspnea and significantly lower PaO₂/FiO₂, and to develop ARDS. In terms of
 348 laboratory finding, leukocytosis ($\geq 10 \times 10^9/L$) but lymphopenia ($< 0.8 \times 10^9/L$) were more
 349 common in severe cases than moderate cases. ALT, LDH, D-dimer and inflammatory markers
 350 including hsCRP and ferritin were significantly higher in severe cases than moderate cases.
 351 Plasma concentrations of both pro-inflammatory cytokines and anti-inflammatory cytokines,
 352 including IL-2R, TNF- α and IL-10 increased in the majority of severe cases and was
 353 significantly higher than did those in moderate cases, suggesting cytokine storms might be
 354 associated with disease severity.

355 Additionally, we also noted that SARS-CoV-2 infection can cause a significant reduction in
 356 peripheral blood lymphocytes and T cell subsets. Although the proportions of T cells subsets
 357 in peripheral blood remained within the normal range in most patients, the prevalence of
 358 decreasing CD4⁺T cell counts and CD8⁺T cell counts was considerably high in both severe
 359 and moderate cases. It is notable that both the proportion and number of B cells were not
 360 frequently decreased in these patients. More importantly, the number of CD4⁺T cells and
 361 CD8⁺T cells was markedly lower in severe cases than moderate cases. Albeit diminished
 362 CD8⁺ T cells, the proportion of HLA-DR⁺ expression on CD8⁺T cells over 35% was more
 363 common in severe cases than those of moderate cases. The expression of HLA-DR on human

T cells has been regarded primarily as a marker of activated T cells. However, It has been recently indicated that CD8⁺ HLA-DR⁺ T cells constitute to a natural subset of Treg and may exert suppressive effect involving CTLA-4 signaling between neighboring T cells¹⁰. Besides, six out of eight severe cases and none of moderate cases with available immunologic data exhibited a broad, significant decline in all the lymphocyte subsets excluding B cells, with total T lymphocyte counts below $400 \times 10^6/L$, CD8⁺T cells below $150 \times 10^6/L$, and NK cells below $<77 \times 10^6/L$, of these six patients, three (50%) eventually died, indicating that SARS-CoV-2 infected patients with severe lymphopenia have high-risk of developing severe COVID-19 and extremely high mortality. Moreover, the production of IFN- γ by CD4⁺T cells but not CD8⁺T cells or NK cells tended to be lower in severe cases than moderate cases. These data suggest that SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4⁺T cells, resulting in diminished number as well as their IFN- γ production, which might be correlated with disease severity of COVID-19.

CD4⁺ T cells play a pivotal role in regulating immune responses, orchestrating the deletion and amplification of immune cells, especially CD8⁺ T cells. CD4⁺ T cells facilitate virus-specific antibody production via the T-dependent activation of B cells¹¹. However, CD8⁺ T cells exert their effects mainly through two mechanisms, cytolytic activities against target cells or cytokines secretion, including IFN- γ , TNF- α , and IL-2 as well as many chemokines¹². The production of IFN- γ is essential for the resistance against infection of various pathogens such as virus, bacteria, and parasite¹³. As a major source of IFN- γ , the ability of T cells to respond to infection is part of the adaptive immune response and takes days to develop a prominent IFN- γ response.

The roles of T cell responses in the context of SARS-CoV and MERS-CoV infection have been previously studied. Likewise, patients who survived SARS-CoV and MERS-CoV infections usually had better immune responses than those who did not¹⁴. The immune system plays an important role in both diseases, but it is differentially affected by the two viruses¹⁵. A study in SARS-CoV mice model has shown that depletion of CD8⁺ T cells at the time of infection does not affect viral replication or clearance. However, depletion of CD4⁺ T cells leads to an enhanced immune-mediated interstitial pneumonitis and delayed clearance of

393 SARS-CoV from the lungs, demonstrating the vital role of CD4⁺ T but not CD8⁺ T cells in
 394 primary SARS-CoV infection ¹⁶. A Chinese study in SARS-CoV-infected patients has
 395 demonstrated that the majority of infiltrative inflammatory cells in the pulmonary interstitium
 396 are CD8⁺ T cells that play an important role in virus clearance as well as in immune-mediated
 397 injury¹⁷. After comparing T cell-deficient mice and B cell-deficient mice, it is found that T
 398 cells are able to survive and kill virus-infected cells in the MERS-CoV infected lung ¹⁸. These
 399 data highlight the importance of T lymphocytes, in particular, CD4⁺ T cells but not B cells in
 400 controlling and finetuning the pathogenesis and outcomes of SARS-CoV and MERS-CoV
 401 infection.

402 Hin Chu et al demonstrated that MERS-CoV but not SARS-CoV can efficiently infect T cells
 403 from the peripheral blood and from human lymphoid organs, and induce apoptosis in T cells,
 404 which involves the activation of both the extrinsic and intrinsic apoptosis pathways. This may
 405 partly explain the lymphopenia observed in MERS-CoV-infected patients¹⁹. The inability of
 406 the SARS-CoV to infect T cells may be ascribed to the lower expression of the SARS-CoV
 407 receptor, angiotensin-converting enzyme 2 expression (ACE2) in T cells^{15,19}. Several recent
 408 structural analyses predict that SARS-CoV-2 also uses ACE2 as its host receptor ²⁰. Therefore,
 409 these findings indicate that T cells might not be susceptible to SARS-CoV-2 infection and
 410 warrants further investigation. Nevertheless, similar to SARS-CoV-2 infection, SARS-CoV
 411 can also significantly decrease peripheral CD4⁺ and CD8⁺ T lymphocyte subsets and it was
 412 related to the onset of illness ²¹. Several potential mechanisms may be involved, including the
 413 development of auto-immune antibodies or immune complexes triggered by viral infection,
 414 directly infecting and promoting the growth inhibition and apoptosis of hematopoietic stem
 415 and progenitor cells, as well as the use of glucocorticoids, which may account for the decrease
 416 of lymphocytes in some SARS patients²².

417 Although nothing is known about mechanism underlying the lymphopenia caused by
 418 SARS-CoV-2 infection, in this present study, some patients were administered
 419 methylprednisolone, the average dosage was a bit higher in severe cases (40-80mg once a day)
 420 than moderate cases (20-40mg once a day). Since corticosteroids have a profound effect on
 421 circulating T lymphocytes, which may involve their movement out of the intra-vascular

422 compartment²³. In this study, we could not exclude the possibility that some of the
 423 lymphopenia may be associated with use of steroids, but it does not account for all the cases,
 424 and certainly not for the lymphopenia at the initial presentation. Further research is required
 425 to determine the effects of corticosteroid on lymphocytes in the patient with COVID-19.

426 Our study has some limitations. First of all, we mainly evaluated the number of T cell subsets
 427 and NK cells as well as their IFN- γ production, the function of these cells, and the role of
 428 activated macrophages and lymphocytes infiltrating lung parenchyma remain unclear. Second,
 429 this study only included a small number of patients, thus the results should be interpreted with
 430 caution, and statistical non-significance may not rule out difference between severe and
 431 moderate cases. Third, since data regarding the viremia profile of SARS-CoV-2 are not
 432 available, further studies are needed to investigate the correlation between the virus load
 433 kinetics and the dynamics of cellular immune responses. Clarification of these questions will
 434 allow further dissection of the complex SARS-CoV-2 pathogenesis, with potential
 435 implications for the development of therapeutics and vaccines.

436 In conclusion, the SARS-CoV-2 infection may affect primarily T lymphocytes, especially
 437 CD4⁺T cells, resulting in significant decrease in number as well as IFN- γ production, which
 438 may be associated with disease severity. Together with clinical characteristics, early
 439 immunologic indicators including diminished T lymphocytes and elevated cytokines may
 440 serve as potential markers for prognosis in COVID-19. Gaining a deeper understanding of the
 441 factors that influence lymphocytes particularly CD4⁺T cell counts and their decrease in
 442 patients with SARS-CoV-2 infection is of importance for clinical management of COVID-19.
 443

444 **Contributors**

445 QN designed the study and had full access to all data in the study and take responsibility for
446 the integrity of data and the accuracy of the data analysis.

447 GC and DW contributed to patient recruitment, data collection, data analysis, data
448 interpretation, literature search, and writing of the manuscript.

449 WG and YC had roles in patient recruitment, data collection, and clinical management.

450 DH, HW, TW and XZ had roles in the experiments, data collection, data analysis, and data
451 interpretation.

452 All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed
453 and approved the final version of the manuscript.

454

455 **Declaration of interests**

456 All authors declare no competing interests.

457

458 **Acknowledgments**

459 This work is funded by grants from Tongji Hospital for Pilot Scheme Project, and partly
460 supported by the Chinese National Thirteenth Five Years Project in Science and Technology
461 (2017ZX10202201).

462

463 **Reference**

- 464 1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients
465 with severe acute respiratory syndrome. *N Engl J Med* 2003; **348**(20): 1967-76.
- 466 2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a
467 novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012; **367**(19):
468 1814-20.
- 469 3. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
470 China, 2019. *N Engl J Med* 2020.
- 471 4. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. *Viruses* 2020;
472 12(2).
- 473 5. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
474 Coronavirus-Infected Pneumonia. *N Engl J Med* 2020.
- 475 6. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019
476 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*
477 2020.
- 478 7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
479 coronavirus in Wuhan, China. *Lancet* 2020.
- 480 8. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus
481 (nCoV) infection is suspected: interim guidance. Jan 11, 2020.
482 [https://www.who.int/internalpublications-](https://www.who.int/internalpublications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected)
483 [detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-\(nco](https://www.who.int/internalpublications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected)
484 [v\)-infection-is-suspected](https://www.who.int/internalpublications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected) (accessed Jan 20, 2020).

485 9. Nanshan Chen MZ, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli
486 Wang, Ying Liu, Yuan Wei, Jia'an Xia, Ting Yu., Xinxin Zhang LZ. Epidemiological and clinical
487 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
488 descriptive study. *Lancet* 2020.

489 10. Arruvito L, Payaslian F, Baz P, et al. Identification and clinical relevance of naturally
490 occurring human CD8+HLA-DR+ regulatory T cells. *J Immunol* 2014; **193**(9): 4469-76.

491 11. Xu X, Gao X. Immunological responses against SARS-coronavirus infection in humans.
492 *Cell Mol Immunol* 2004; **1**(2): 119-22.

493 12. Frasca L PC, Piccolella E. CD4+ T cells orchestrate both amplification and deletion of
494 CD8+ T cells. *Crit Rev Immunol*. 1998;18(6):569-94.

495 13. Taylor GA, Feng CG, Sher A. p47 GTPases: regulators of immunity to intracellular
496 pathogens. *Nat Rev Immunol* 2004; **4**(2): 100-9.

497 14. Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients
498 with Middle East respiratory syndrome coronavirus infection. *Ann Intern Med* 2014; **160**(6):
499 389-97.

500 15. Ying T, Li W, Dimitrov DS. Discovery of T-Cell Infection and Apoptosis by Middle East
501 Respiratory Syndrome Coronavirus. *J Infect Dis* 2016; **213**(6): 877-9.

502 16. Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe acute
503 respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T
504 cells are important in control of SARS-CoV infection. *J Virol* 2010; **84**(3): 1289-301.

505 17. Zhao JM, Zhou GD, Sun YL, et al. [Clinical pathology and pathogenesis of severe acute
506 respiratory syndrome]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2003; **17**(3):

507 217-21.

508 18. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle
509 East respiratory syndrome. *Proc Natl Acad Sci U S A* 2014; **111**(13): 4970-5.

510 19. Chu H, Zhou J, Wong BH, et al. Middle East Respiratory Syndrome Coronavirus
511 Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic
512 Apoptosis Pathways. *J Infect Dis* 2016; **213**(6): 904-14.

513 20. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus
514 from Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol* 2020.

515 21. He Z ZC, Dong Q, Zhuang H, Song S, Peng G, Dwyer DE. Effects of severe acute
516 respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their
517 subsets. *Int J Infect Dis* 2005; **9**(6):323-30.

518 22. Yang M, Li CK, Li K, et al. Hematological findings in SARS patients and possible
519 mechanisms (review). *Int J Mol Med* 2004; **14**(2): 311-5.

520 23. Cupps TR, Fauci AS. Corticosteroid-mediated immunoregulation in man. *Immunol Rev*
521 1982; **65**: 133-55.

522

523

524 **Figure legend**

525 Figure 1: Computed tomography of the chest of patients with COVID-19

526 Chest CT axial view lung window from a 62-year-old female with severe COVID-19 showing
527 bilateral ground-glass opacity and subsegmental areas of consolidation on day 6 after
528 symptom onset (A), and typical presentation of a “white lung” appearance with bilateral
529 multiple lobular and subsegmental areas of consolidation on day 8 after symptom onset (B).
530 Chest CT axial view lung window from a 32-year-old male with moderate COVID-19
531 showing bilateral ground-glass opacity on day 7 after symptom onset (C), and resolved
532 bilateral ground-glass opacity on day 11 after symptom onset (D).

533

534 Figure 2: Number of immune cell subsets and proportion of IFN- γ expression in patients with
535 COVID-19

536 (A) Flow cytometry staining of natural killer (NK) cells, CD4⁺T cells, CD8⁺T cells and Treg
537 as well as production of IFN- γ by CD4⁺T cells, CD8⁺T cells and NK cells from a
538 representative patient.

539 (B) A series of comparisons of absolute number of total T&B lymphocytes, CD4⁺T cells,
540 CD8⁺T cells and NK cells between severe cases and moderate cases. Data are expressed as
541 mean $\pm$ SEM.

542 (C) A series of comparisons of production of IFN- γ by CD4⁺T cells, CD8⁺T cells and NK
543 cells between severe cases and moderate cases. Data are expressed as mean $\pm$ SEM.

544

545 **Table 1 Demographics and baseline characteristics of patients with COVID-19**

	All patients (n=21)	severe cases (n=11)	moderate cases (n=10)	P value
Characteristics				
Males, n (%)	17 (81.0%)	10 (90.9%)	7 (70.0%)	0.31
Age, yrs	56.3 (14.3)	63.9 (9.6)	51.4 (13.7)	0.038
>50	15 (71.4%)	10 (90.9%)	5 (50.0%)	0.043
Huanan seafood market exposure, n (%)	4 (19.4%)	1 (9.1%)	3 (30.0%)	0.31
Any comorbidity, n (%)	7 (33.3%)	5 (45.5%)	2 (20.0%)	0.36
Hypertension, n (%)	5 (23.8%)	4 (19.0%)	1 (10.0%)	0.31
Diabetes, n (%)	3 (14.3%)	2 (18.2%)	1 (10.0%)	1.00
Signs and symptoms				
Fever, n/N (%)	20/20 (100%)	10/10 (100%)	10/10 (100%)	NA
Highest temperature, °C	38.8 (0.54)	38.8 (0.69)	38.8 (0.26)	0.85
38.1-39.0 °C, n/N (%)	12/19 (63.2%)	5/9 (55.6%)	7/10 (70.0%)	0.52
>39.0 °C, n/N (%)	7/19 (36.8%)	4/9 (44.4%)	3/10 (30.0%)	..
Cough, n/N (%)	16/20 (80.0%)	7/10 (70.0%)	9/10 (90.0%)	0.58
Fatigue, n/N (%)	17/20 (85.0%)	10/10 (100.0%)	7/10 (70.0%)	0.21
Myalgia, n/N (%)	8/20 (40.0%)	5/10 (50.0%)	3/10 (30.0%)	0.65
Sputum production, n/N (%)	5/20 (25%)	2/10 (20.0%)	3/10 (30.0%)	1.00
Headache, n/N (%)	2/20 (10.0%)	1/10 (10.0%)	1/10 (10.0%)	1.00
Diarrhea, n/N (%)	4/20 (20.0%)	1/10 (10.0%)	3/10 (30.0%)	0.58
Chest tightness, n/N (%)	11/20 (55.0%)	8/10 (80.0%)	3/10 (30.0%)	0.07
Coma, n (%)	1 (4.8%)	1 (9.1%)	0 (0.0%)	1.00
Dyspnea, n (%)	11 (52.4%)	11 (100.0%)	0 (0.0%)	0.000
Days from illness onset	8.6 (3.9)	8.6 (3.9)	NA	NA

to dyspnea				
Systolic pressure, mm Hg	125.7 (19.6)	131.5 (21.5)	119.3 (15.0)	0.17
Heart rate, bpm	90.0 (14.8)	90.5 (18.6)	89.6 (8.9)	0.90
Respiratory rate, per min	24.0 (5.6)	27.3 (6.1)	20.4 (0.6)	0.003
>24 breaths per min, n (%)	8 (38.1%)	8 (72.7%)	0 (0.0%)	0.001
PaO ₂ /FiO ₂	220.2 (142.5)	122.9 (45.6)	366.2 (110)	0.002
>300, n/N (%)	3/10 (30.0%)	0/6 (0.0%)	3/4 (75%)	0.011
200-300, n/N (%)	2/10 (20.0%)	1/6 (16.7%)	1/4 (25%)	..
100-200, n/N (%)	2/10 (20.0%)	2/6 (33.3%)	0/4 (0.0%)	..
≤100, n/N (%)	3/10 (30.0%)	3/6 (50.0%)	0/4 (0.0%)	..

546 Data are mean (S.D.), n (%), or n/N (%), where N is the total number of patients with
547 available data. p values comparing severe cases and moderate cases are from χ^2 test, Fisher's
548 exact test, or Mann-Whitney U test.
549

550 **Table 2 Laboratory findings and chest CT images of patients with COVID-19 on**
551 **admission**

	All patients (n=21)	severe cases (n=11)	moderate cases (n=10)	P value
White blood cell count, $\times 10^9/L$	7.0 (3.6)	9.2 (3.6)	4.7 (1.5)	0.002
<4, n (%)	3 (14.3%)	0 (0.0%)	3 (30.0%)	0.017
4-10, n (%)	15 (%)	8 (%)	7 (70.0%)	..
≥ 10 , n (%)	3 (%)	3 (%)	0 (0.0%)	..
Neutrophil count, $\times 10^9/L$	5.7 (3.8)	8.0 (3.7)	3.1 (1.3)	0.001
Lymphocyte count, $\times 10^9/L$	0.9 (0.4)	0.7 (0.3)	1.1 (0.3)	0.048
<0.8, n (%)	9 (42.9%)	8 (72.7%)	1 (10.0%)	0.008
Hemoglobin, g/L	137.0 (17.4)	138.1 (15.9)	135.8 (18.4)	0.78
Platelet count, $\times 10^9/L$	162.7 (45.0)	164.2 (45.8)	161.0 (44.2)	0.88
<100, n (%)	1 (4.8%)	0 (0.0%)	1 (10.0%)	0.48
Alanine aminotransferase, U/L	30.0 (16.5)	41.4 (14.9)	17.6 (5.8)	0.0002
Aspartate aminotransferase, U/L	38.2 (24.6)	51.0 (28.3)	24.2 (4.1)	0.011
>40, n (%)	6 (28.6%)	5 (45.5%)	0 (0.0%)	0.035
Albumin, g/L	34.4 (5.7)	31.5 (5.5)	37.6 (4.0)	0.013
Total bilirubin, mmol/L	9.8 (5.6)	11.2 (6.4)	8.2 (3.8)	0.24
Blood urea nitrogen, mmol/L	6.1 (3.3)	7.7 (3.7)	4.2 (1.3)	0.014

mmol/l				
Creatinine, $\mu\text{mol/L}$	82.4 (30.3)	90.7 (38.5)	73.3 (11.6)	0.21
Creatine kinase, U/L	153.7 (123.1)	208.3 (122.4)	106.9 (102.8)	0.16
Lactate	408.1 (231.0)	567.2 (217.1)	234.4 (46.7)	0.0002
dehydrogenase, U/L				
Prothrombin time, s	13.8 (1.0)	14.1 (0.9)	13.4 (1.0)	0.15
Activated partial thromboplastin time, s	40.0 (6.5)	36.2 (5.8)	44.6 (3.7)	0.002
D-dimer, $\mu\text{g/mL}$	4.0 (7.0)	8.2 (9.0)	0.4 (0.3)	0.025
Procalcitonin, ng/mL	0.3 (0.5)	0.5 (0.6)	0.1 (0.1)	0.073
<0.1, n/N (%)	7/18 (38.9)	0/10 (0.0%)	7/8 (87.5%)	0.002
0.1-0.25, n/N (%)	6/18 (33.3%)	6/10 (60.0%)	0/8 (0.0%)	..
0.25-0.5, n/N (%)	2/18 (11.1%)	1/10 (10.0%)	1/8 (12.5%)	..
≥ 0.5 , n/N (%)	3/18 (16.7%)	3/10 (30.0%)	0/8 (0.0%)	..
High-sensitivity C-reactive protein, mg/L	97.5 (66.4)	135.2 (52.4)	51.4 (50.8)	0.003
>60, n/N (%)	14/20 (70%)	11/11 (100.0)	3/9 (33.3%)	0.002
Ferritin, $\mu\text{g/L}$	1284.8 (934)	1734.4 (585.6)	880.2 (1001.0)	0.049
>800, n/N (%)	12/19 (63.2%)	9/9 (100.0%)	3/10 (30.0%)	0.003
Bilateral involvement of chest computed tomography scan on admission	17/21 (81.0%)	10/11 (90.9%)	7/10 (70%)	0.31

552 Data are mean (S.D.) or n/N (%), where N is the total number of patients with available data.
553 p values comparing severe cases and moderate cases are from χ^2 , Fisher's exact test, or
554 Mann-Whitney U test.

556 **Table 3 Immunologic features of patients with COVID-19**

	All patients (n=21)	severe cases (n=11)	moderate cases (n=10)	P value	Normal range
Plasma cytokines					
IL-1 β increased, n/N (%)	1/16 (6.2%)	1/9 (11.1%)	0/7 (0.0%)	1.00	<5
IL-2R, U/mL	869.6 (486.2)	1202.4 (380.2)	441.7 (169.9)	0.0004	223-710
increased, n/N (%)	9/16 (56.3%)	8/9 (88.9%)	1/7 (14.3%)	0.009	
IL-6, pg/mL	51.2 (59.4)	73.8 (67.9)	18.8 (13.9)	0.066	<7
increased, n/N (%)	13/16 (81.3%)	8/9 (88.9%)	5/7 (71.4%)	0.55	
IL-8, pg/mL	45.6 (56.2)	61.8 (67.1)	24.7 (25.4)	0.21	<62
increased, n/N (%)	3/16 (18.8%)	2/9 (22.2%)	1/7 (14.3%)	1.00	
IL-10, pg/mL	9.0 (2.9)	10.9 (1.8)	6.6 (2.1)	0.001	<9.1
increased, n/N (%)	9/16 (56.3%)	7/9 (77.8%)	2/7 (28.6%)	0.12	
TNF- α , pg/mL	9.4 (3.0)	10.9 (3.0)	7.5 (1.6)	0.023	<8.1
increased, n/N (%)	11/16 (68.8%)	8/9 (88.9%)	3/7 (42.9%)	0.11	
>10 pg/mL, n/N (%)	7/16 (43.8%)	7/9 (77.8%)	0/7 (0.0%)	0.003	
Peripheral immune cell subsets					
Total T lymphocytes (%)	61.6 (10.5)	56.1 (9.5)	69 (6.3)	0.020	50-84


Total T lymphocytes count, $\times 10^6/L$	479.9 (259.8)	332.5 (207.9)	676.5 (179.7)	0.011	955-2860
decreased, n/N (%)	13/14 (92.9%)	8/8 (100.0%)	5/6 (83.3%)	0.43	
<400, n/N (%)	6/14 (42.9%)	6/8 (75.0%)	0/6 (0.0%)	0.010	
Total B lymphocytes count, $\times 10^6/L$	20.3 (12.7)	26.5 (13.1)	12.0 (5.3)	0.036	5-18
increased, n/N (%)	7/14 (50.0%)	6/8 (75.0%)	1/6 (16.7%)	0.10	
Total B lymphocytes count, $\times 10^6/L$	144.6 (95.6)	165.1 (114.6)	117.2 (50.2)	0.39	90-560
decreased, n/N (%)	4/14 (28.6%)	3/8 (37.5%)	1/6 (16.7%)	0.58	
CD4 ⁺ T cells, (%)	34.7 (8.4)	33.4 (8.8)	36.3 (7.5)	0.56	27-51
CD4 ⁺ T cells count, $\times 10^6/L$	260 (138.9)	185.6 (101.4)	359.2 (118.7)	0.018	550-1440
decreased, n/N (%)	14/14 (100.0%)	8/8 (100.0%)	6/6 (100.0%)	NA	
CD8 ⁺ T cells, (%)	23.0 (8.3)	19.6 (6.5)	27.5 (8.4)	0.093	15-44
CD8 ⁺ T cells count, $\times 10^6/L$	187.6 (129.3)	124.3 (107.9)	272.0 (105.0)	0.035	320-1250
decreased, n/N (%)	12/14 (85.7%)	7/8 (87.5%)	5/6 (83.3%)	1.00	
<150, n/N (%)	6/14 (42.9%)	6/8 (75.0%)	0/6 (0.0%)	0.010	
NK cells, (%)	16.9 (9.6)	15.7 (9.9)	18.5 (8.9)	0.62	7-40
NK cells count, $\times 10^6/L$	134.7 (104.7)	106.1 (117.7)	172.8 (67.7)	0.27	150-1100
decreased, n/N (%)	8/14 (57.1%)	6/8 (75.0%)	2/6 (33.3%)	0.28	

<77, n/N (%)	6/14 (42.9%)	6/8 (75.0%)	0/6 (0.0%)	0.010	
CD28 ⁺ CD4 ⁺ T cells/	97.7 (1.8)	97.7 (1.5)	97.7 (2.2)	0.99	84.11-100.00
CD4 ⁺ T, %					
CD28 ⁺ CD8 ⁺ T cells/	60.9 (17.7)	53.8 (19.8)	69.9 (8.4)	0.22	48.04-77.14
CD8 ⁺ T, %					
HLA-DR ⁺ CD8 ⁺ T	41.5 (12.4)	46.8 (6.9)	34.7 (14.3)	0.19	20.73-60.23
cells/ CD8 ⁺ T, %					
>35%, n/N (%)	6/9 (66.7%)	5/5 (100%)	1/4 (25.0%)	0.048	
CD45RA ⁺ CD4 ⁺ T	36.8 (11.0)	39.1 (12.5)	33.8 (7.6)	0.54	29.41-55.41
cells/ CD4 ⁺ T, %					
CD45RO ⁺ CD4 ⁺ T	63.2 (11.0)	60.9 (12.5)	66.2 (7.6)	0.54	44.44-68.94
cells/ CD4 ⁺ T, %					
Treg, %	3.98 (1.4)	3.9 (1.7)	4.0 (0.5)	0.92	5.36-6.30
CD45RA ⁺ Treg, %	0.76 (0.4)	0.5 (0.3)	1.1 (0.2)	0.019	2.07-4.55
CD45RO ⁺ Treg, %	3.2 (1.3)	3.5 (1.7)	2.9 (0.5)	0.62	1.44-2.76
IFN- γ expressing	19.4 (8.4)	14.6 (5.5)	23.6 (8.4)	0.063	14.54-36.96
CD4 ⁺ T cells, %					
IFN- γ expressing	48.8 (9.7)	46.6 (10.7)	50.7 (8.3)	0.49	34.93-87.95
CD8 ⁺ T cells, %					
IFN- γ expressing	71.5 (11.0)	67.4 (8.8)	75.0 (11.4)	0.25	61.2-92.65
NK cells, %					


557 Data are mean (S.D.) or n/N (%), where N is the total number of patients with available data.
558 p values comparing severe cases and moderate cases are from χ^2 , Fisher's exact test, or
559 Mann-Whitney U test.

560



A Case 1 first chest CT




B Case 1 second chest CT




C Case 2 first chest CT




D Case 2 second chest CT



A



B



C

